Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 20/20 | 0.73 |
| ▸ | CSF1R | P07333 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6341424 | 0.87 | PDGFRB (0.72) | PDGFRBCSF1RKITFLT3 | |
| SCHEMBL906249 | 0.87 | PDGFRB (0.96) | PDGFRBCSF1RKITFLT3 | |
| SCHEMBL6336760 | 0.84 | PDGFRB (0.76) | PDGFRBKITFLT3 | |
| SCHEMBL6337797 | 0.83 | PDGFRB (0.76) | PDGFRBCSF1RKITFLT3 | |
| SCHEMBL6405114 | 0.79 | PDGFRB (0.60) | PDGFRBKITFLT3 | |
| SCHEMBL13330468 | 0.79 | PDGFRB (0.88) | PDGFRBCSF1RKITFLT3 | |
| SCHEMBL3366664 | 0.79 | PDGFRB (0.88) | PDGFRB | |
| SCHEMBL6336471 | 0.79 | PDGFRB (0.59) | PDGFRBKITFLT3 | |
| SCHEMBL3902359 | 0.77 | PDGFRB (0.72) | PDGFRBCSF1RKITFLT3 | |
| SCHEMBL6344574 | 0.77 | PDGFRB (0.66) | PDGFRBKITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960580-B2 | Nitrogenous heterocyclic substituted quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | claimed |
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | claimed |
| US-6960580-B2 | Nitrogenous heterocyclic substituted quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-01 | — | — | US | disclosed |
| EP-1490362-A2 | (HOMO)PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | Millennium Pharmaceuticals, Inc. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-01-02 | — | — | US | disclosed |
| WO-2002072578-A2 | (HOMO) PIPERAZINE SUBSTITUTED QUINOLINES FOR INHIBITING THE PHOSPHORYLATION OF KINASES | MILLENNIUM PHARMACEUTICALS (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004158-A1 | Nitrogen containing heterocyclic quinoline compounds | WNK2, PDGFA, PDGFRA | PDGFRB 6/4885CSF1R 741/4885KIT 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.